NT5E and non-small cell lung carcinoma: Oleclumab (anti-CD73 mAb) enhanced progression free survival in combination with durvalumab in patients with unresectable stage III non-small-cell lung cancer. PACIFIC-9 continues as subsequently active Phase III trial